PCAT PCAT dumps - 100% Pass Guarantee!

Which of the following is NOT made by the pituitary gland?

A. ACTH

B. ADH

C. FSH

D. LH

Which of the following polysaccharides is largely stored in the liver and muscles?

A. Cellulose

B. Starch

C. Glycogen

D. Inulin

Which of the following alcohols is the most easily dehydrated?

A. (CH3)3C-OH

B. (CH3)2CH-OH

C. CH3CH2-OH

D. CH3-OH

For most Americans, the words "Alzheimer's disease" (AD) ?often mispronounced purposefully or accidentally as "old timers' disease" ?signify devastating memory loss and stigma. The information about AD ?often learned solely through the media ?may lead individuals to believe that AD is inevitable (it isn't), and possibly think that all AD patients receive poor care (there are many remarkably good AD units). Many individuals may envision a future burdened with more dementia patients and fewer societal resources to help support them (a real possibility). In general, pharmacists are well aware of what AD is and isn't. AD is complex and relentlessly progressive; it affects patients, loved ones, and caregivers adversely. Pharmacists can provide pertinent information about AD's myths, realities, and available symptomatic treatments. AD's harbinger is language difficulties, which include aphasia (language disturbance), apraxia (inability to carry out motor functions), and agnosia (failure to recognize or identify objects). Consequently, those with AD will often create new words for items. They may call a pencil a "list writer," or a key a "door turner." Clinicians stage AD as mild, moderate, or severe depending on the patient's cognitive and memory impairment, communication problems, personality changes, behavior, and loss of control of bodily functions. People often dismiss mild AD as normal cognitive decline or senility ?in other words, "normal" aging. For this reason, most people don't seek treatment and are diagnosed in the late-mild to early-moderate stage. In the severe stage, difficulty swallowing elevates the risk of aspiration pneumonia, which often marks the beginning of the downward spiral that ultimately ends with death; AD has no cure. A handful of pharmacologic treatments ?acetylcholinesterase inhibitors and N-methyl-D-aspartate antagonists ?alter the decline trajectory. These treatments slow disease progression, enhance cognitive function, delay cognitive decline, and decrease disruptive behaviors. Not all patients respond to these medications, but experts generally believe that those who do will show mild to moderate improvements for 6 months to a year. Although the drugs' effects are short-lived, they improve patients' quality of life and briefly enable independence. Determining when medications stop providing a therapeutic benefit and should be discontinued is challenging. Clinicians use various methods to monitor decline, including mental status tools, patient self-report, and loved ones' observations. Most clinicians continue drug treatment if the patient seems to tolerate the medication well, can afford it, and if there seems to be a benefit. With disease progression, specific behavioral symptoms including depression, agitation, hallucinations, and sleep disturbances become concerns. Antianxiety drugs, antipsychotics, and antidepressants are sometimes used to alleviate symptoms, but effective behavioral strategies are much preferred.

The final paragraph primarily serves to: A. Detail the transition from early stage Alzheimer's to the severe stages of the disease.

B. Outline the different treatment options available to patients.

C. Explain how patients decide which treatment to pursue.

D. Describe how health care professionals decide when to terminate treatment.

Express 8% as a fraction.

A. 4/25

B. 4/100

C. 2/50

D. 2/25